Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Free Cash Flow (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Free Cash Flow for 4 consecutive years, with -$58.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 173.29% to -$58.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$181.0 million, a 38.87% decrease, with the full-year FY2024 number at -$142.1 million, up 11.48% from a year prior.
  • Free Cash Flow was -$58.5 million for Q3 2025 at Centessa Pharmaceuticals, down from -$22.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$21.4 million in Q3 2024 to a low of -$60.1 million in Q2 2022.
  • A 4-year average of -$42.8 million and a median of -$42.8 million in 2024 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 44.67% in 2025; the steepest drop was 173.29% in 2025.
  • Centessa Pharmaceuticals' Free Cash Flow stood at -$52.2 million in 2022, then skyrocketed by 40.48% to -$31.1 million in 2023, then tumbled by 37.72% to -$42.8 million in 2024, then tumbled by 36.79% to -$58.5 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Free Cash Flow are -$58.5 million (Q3 2025), -$22.5 million (Q2 2025), and -$57.2 million (Q1 2025).